Contact
Please use this form to send email to PR contact of this press release:
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
TO:
Please use this form to send email to PR contact of this press release:
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
TO: